Market Research Future
Bone Graft Substitute Market is expected to expand at 6.52% CAGR during the forecast period 2019 to 2027 Bone Graft Substitute Market – Scenario Market Research Future (MRFR)’s latest study reveals that the global bone graft substitutes market is expected to expand at 6.52% CAGR during the forecast period 2017 to 2027. The market is set to reach a valuation of USD 5,031 Mn by the end of the assessment period. The increasing prevalence of diseases related to bones has intensified the demand for bone graft substitutes. Additionally, the rising awareness about the developments in bone graft substitutes coupled with rising healthcare expenditure is likely to augment the market size and revenue over the next couple of years. The painful procedure related to autografts have paved the way for developments in the bone graft substitutes market. Hence, the demand for alternatives such as allografts, xenografts, and synthetic bone grafts has been on the rise. It is projected to aid the proliferation of the market in the forthcoming years by accelerating its adoption. Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/1195 The growth of the bone graft substitutes market is guided by the factors such as increasing orthopedic problems, exponential geriatric population, and rising demand for reconstructive orthopedic treatments. The adoption of bone graft substitutes in the oral healthcare sector is another factor responsible for catalyzing the growth of the bone graft substitutes market through the assessment period. The bone graft substitutes market is poised to remain highly lucrative in the foreseeable future. However, risks associated with disease transmission in allografts and xenograft as well as graft rejection, improper fixation, etc. are prognosticated to restrict the market expansion over the forecast period. Competitive Analysis Sone of the key players profiled in the report includes ACE Surgical Supply Company, Inc., Dentium Co., Ltd., BioHorizons IPH, Inc., Dentsply Sirona, Medtronic plc, Stryker Corporation, Zimmer Biomet, and Institut Straumann AG. Industry Developments: In August 2018, BoneSupport, a Scandinavian orthobiologics company, won Health Canada approval for Cerament G bone graft substitute. In September 2018, Baxter International Inc., an American healthcare company, received FDA clearance for its Actifuse Flow bone graft substitute. It shall be used in orthopedic surgical procedures. Segments: